中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.036 seconds)

    PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES DIRECTED AGAINST THE HERV-W ENVELOPE
    31.
    发明申请
    PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES DIRECTED AGAINST THE HERV-W ENVELOPE 审中-公开
    含有针对HERV-W包装的抗体的药物组合物

    公开(公告)号：US20100074894A1

    公开(公告)日：2010-03-25

    申请号：US12449327

    申请日：2008-02-11

    Applicant: Herve Perron

    Inventor： Herve Perron

    IPC: A61K39/395 ,  A61P31/12 ,  C07K16/08

    CPC classification number: C07K16/1036 ,  A61K2039/505

    Abstract: A pharmaceutical composition that contains, as an active ingredient, at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the binding site between said env protein and the hASCT1 or hASCT2 receptor.

    Abstract translation: 除了特异性针对所述env蛋白和hASCT1或hASCT2受体之间的结合位点的任何抗体外，其含有针对HERV-W包膜蛋白的至少一种抗体作为活性成分的药物组合物。

    Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
    33.
    发明授权
    Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease 失效
    使用多肽来检测，预防或治疗与退行性，神经性或自身免疫疾病相关的病理状况

    公开(公告)号：US07510843B2

    公开(公告)日：2009-03-31

    申请号：US11450360

    申请日：2006-06-12

    Applicant: Dominique Roecklin ,  Hanno Kolbe ,  Marie-Helene Charles ,  Carine Malcus ,  Lyse Santoro ,  Herve Perron

    Inventor： Dominique Roecklin ,  Hanno Kolbe ,  Marie-Helene Charles ,  Carine Malcus ,  Lyse Santoro ,  Herve Perron

    IPC: G01N33/53 ,  C07K16/18

    CPC classification number: G01N33/564 ,  A61K38/1709 ,  C07K14/47 ,  G01N33/6896 ,  G01N2800/52

    Abstract: The invention concerns the use of at least one polypeptide comprising a protein fragment to obtain a diagnostic, prognostic, prophylactic or therapeutic composition for detecting, preventing or treating a pathological condition associated with a degenerative and/or neurological and/or autoimmune disease, said protein being selected among the proteins whereof the peptide sequence in native state corresponds to SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10, SEQ ID No 11, SEQ ID No 12, SEQ ID No 13, SEQ ID No 14, SEQ ID No 15, SEQ ID No 16, SEQ ID No 17, SEQ ID No 18, SEQ ID No 19, SEQ ID No 20, SEQ ID No 21, SEQ ID No 22, SEQ ID No 23, SEQ ID No 24, SEQ ID No 25, SEQ ID No 26, SEQ ID No 27, SEQ ID No 28, and SEQ ID No 29, and the peptide sequences having at least 70% identity, preferably at least 80% identity and advantageously at least 98% identity with any one of the peptide sequences SEQ ID No 1 to SEQ ID No 8 and SEQ ID No 10 to SEQ ID No 29, and the peptide sequences or fragments of said sequences belonging to a common family of proteins selected among perlecan, the precursor of the retinol-binding plasmatic protein, of the GM2 activator protein, of calgranulin B and of saponin B.

    Abstract translation: 本发明涉及使用包含蛋白质片段的至少一种多肽以获得用于检测，预防或治疗与退行性和/或神经和/或自身免疫疾病相关的病理状况的诊断，预后，预防或治疗组合物，所述蛋白质 选自天然状态的肽序列的蛋白质对应于SEQ ID No 1，SEQ ID No 2，SEQ ID No 3，SEQ ID No 4，SEQ ID No 5，SEQ ID No 6，SEQ ID No 7，SEQ ID No 8，SEQ ID No 9，SEQ ID No 10，SEQ ID No 11，SEQ ID No 12，SEQ ID No 13，SEQ ID No 14，SEQ ID No 15，SEQ ID No 16，SEQ ID No 17，SEQ ID No 18，SEQ ID No 19，SEQ ID No 20，SEQ ID No 21，SEQ ID No 22，SEQ ID No 23，SEQ ID No 24，SEQ ID No 25，SEQ ID No 26，SEQ ID No 27，SEQ ID No 28和SEQ ID No 29，以及肽序列与肽序列SEQ ID No.1至SEQ ID NO：1至SEQ ID NO：1中的任何一个具有至少70％同一性，优选至少80％同一性，有利地至少98％的同一性 ID No 8和SEQ ID No 10至SEQ ID No 29，并且属于共同家族蛋白质的所述序列的肽序列或片段，其选自Perlecan，视黄醇结合性血浆蛋白的前体，GM2激活蛋白， 的钙粒蛋白B和皂角苷B.

    Isolated cytotoxic factor associated with multiple sclerosis and method of detecting said cytotoxic factor
    35.
    发明申请
    Isolated cytotoxic factor associated with multiple sclerosis and method of detecting said cytotoxic factor 失效
    与多发性硬化相关的分离的细胞毒性因子和检测所述细胞毒性因子的方法

    公开(公告)号：US20070065881A1

    公开(公告)日：2007-03-22

    申请号：US10582674

    申请日：2004-12-22

    Applicant: Herve Perron ,  Anne Eveno-Nobile ,  Jacques Portoukalian ,  Nicole Battail-Poirot

    Inventor： Herve Perron ,  Anne Eveno-Nobile ,  Jacques Portoukalian ,  Nicole Battail-Poirot

    IPC: G01N33/567 ,  C07K14/705

    CPC classification number: G01N33/564 ,  C07K14/47 ,  C07K14/52 ,  C07K16/18 ,  C07K16/24 ,  C07K16/3084 ,  C07K2317/32 ,  G01N2800/285

    Abstract: The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.

    Abstract translation: 本发明涉及与多发性硬化相关并且选自异型复合体GM2AP / GM2 / MRP14和突变的GM2AP / GM2 / MRP14的分离的细胞毒性因子，以及检测待测生物样品中所述因子的方法。 本发明的方法包括以下步骤：（i）将生物样品与至少一种选自与GM2AP蛋白特异性结合的抗体，至突变型GM2AP蛋白，至MRP14蛋白的捕获抗体接触至复合物 GM2AP / GM2，复合突变的GM2AP / GM2和复合物MRP14 / GM2，以及至少一种选自与GM2AP蛋白特异性结合的抗体的标记检测抗体与突变的GM2AP蛋白相关的MRP14蛋白，至 复合体GM2AP / GM2，复合突变的GM2AP / GM2和复合物MRP14 / GM2，以及（ii）通过检测和/或定量标记的检测抗体来检测和/或定量细胞毒性因子。

    Cell lines and viral isolates associated with multiple sclerosis
    39.
    发明授权
    Cell lines and viral isolates associated with multiple sclerosis 有权
    与多发性硬化相关的细胞系和病毒分离物

    公开(公告)号：US06342383B1

    公开(公告)日：2002-01-29

    申请号：US09133411

    申请日：1998-08-13

    Applicant: Herve Perron ,  Francois Mallet ,  Bernard Mandrand ,  Frederic Bedin ,  Frederic Beseme

    Inventor： Herve Perron ,  Francois Mallet ,  Bernard Mandrand ,  Frederic Bedin ,  Frederic Beseme

    IPC: C12N112

    CPC classification number: C07K14/005 ,  A61K38/00 ,  C12N7/00 ,  C12N2740/10021 ,  C12N2740/10022 ,  Y10S435/912

    Abstract: Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of said virus, and a second agent, or a variant of said second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8 1993 under Accession Number V93010816, and from their variant strains.

    Abstract translation: 包含与多发性硬化相关的两种致病和/或感染因子的组合物，即由具有逆转录酶活性并与内源性逆转录病毒元件家族相关的人病毒或所述病毒的变体组成的第一药剂和第二药剂， 或所述第二药剂的变体，这两种源自相同病毒株的两种致病和/或感染剂分别选自1992年7月22日以保藏号V92072202和EC7PG保藏的ECACC分别保藏的POL-2的菌株 1993年1月8日的ECACC，保藏号V93010816，以及他们的变异株。

Patent Agency Ranking